Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BGMA Urges UK To Hold Firm On Trade Deals

Insists Patent And Exclusivity Provisions Must Not Block Access

Executive Summary

Responding to UK government statements on the country’s future approach to trade deals with non-EU nations, the BGMA has insisted that there must be no changes to patent and exclusivity provisions that would block market entry for generic and biosimilar medicines.

You may also be interested in...



Who’s Hired? Stada Makes Moves In Germany And Poland

Stada has appointed general managers for its businesses in Germany and Poland. Meanwhile, US and UK industry associations the AAM and BGMA have announced appointments, Glenmark has added an ex-Teva executive to its board of directors and the MHRA has named a new chair.

UK-US Trade Deal Benefits From Biologic Exclusivity ‘Commitment’

The US Trade Representative Robert Lighthizer has intimated that a controversial provision requiring 10 years of biologic data exclusivity would not be contained in a proposed free trade agreement with the UK, as it seeks partners following its exit from the EU.

UK-US Free Trade Deal Plans Disappoint Industry

The UK has published its negotiating mandate for talks on a free trade deal with the US. As expected, intellectual property protection figures prominently, but the life sciences industry sees little merit in the government’s approach. It also warns that the UK’s future relationship with the EU could lead to greater regulatory burdens and costs.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel